Characteristic | Taxanes (n=13 654) | Vinca alkaloids (n=4772) | P value |
Age, n (%) | <0.001 | ||
18–39 years | 449 (3.3) | 616 (12.9) | |
40–59 years | 4274 (31.3) | 1232 (25.8) | |
60–79 years | 8287 (60.7) | 2661 (55.8) | |
≥80 years | 644 (4.7) | 263 (5.5) | |
Gender, n (%) | <0.001 | ||
Male | 5036 (37.3) | 2521 (54.1) | |
Female | 8469 (62.7) | 2138 (45.9) | |
Year of reporting, n (%) | 0.0002 | ||
Before 2000 | 1098 (8.0) | 473 (9.9) | |
2000–2009 | 3639 (26.7) | 1208 (25.3) | |
2010–2014 | 2949 (21.6) | 1073 (22.5) | |
After 2014 | 5968 (43.7) | 2018 (42.3) | |
Reporting source, n (%) | 0.01 | ||
Consumer | 54 (0.4) | 37 (0.8) | |
Pharmaceutical company | 11 872 (87.0) | 4114 (86.2) | |
Healthcare professional | 851 (6.2) | 301 (6.3) | |
Other | 877 (6.4) | 320 (6.7) | |
Cardiovascular disease, n (%)* | |||
Hypertension requiring hospitalisation | 3415 (25.0) | 961 (20.1) | <0.001 |
Heart failure | 2312 (16.9) | 1157 (24.3) | <0.001 |
Atrial fibrillation | 1461 (10.7) | 641 (13.4) | <0.001 |
Pericardial disease/effusion | 129 (0.9) | 57 (1.2) | 0.14 |
Venous thromboembolism | 2927 (21.4) | 1092 (22.9) | 0.04 |
Myocardial infarction | 1519 (11.1) | 607 (12.7) | 0.003 |
Ischaemic stroke | 1039 (7.6) | 380 (8.0) | 0.43 |
Indication for treatment, n (%) | |||
Breast cancer | 3554 (26.0) | 190 (4.0) | <0.001 |
Lung cancer | 2632 (19.3) | 414 (8.7) | <0.001 |
Prostate cancer | 786 (5.8) | 16 (0.3) | <0.001 |
Lymphoma | 16 (0.1) | 2455 (51.5) | <0.001 |
Leukaemia | 62 (0.5) | 394 (8.3) | <0.001 |
Ovarian cancer | 1269 (9.3) | 8 (0.2) | |
Co-reported medications in the drug report, n (%) | |||
Anthracycline | 1221 (8.9) | 2296 (48.1) | <0.001 |
HER2Neu inhibitors | 1691 (12.4) | 97 (2.0) | <0.001 |
Tyrosine kinase inhibitors | 120 (0.9) | 151 (3.2) | <0.001 |
Checkpoint inhibitors | 828 (6.1) | 37 (0.8) | <0.001 |
*Proportion of all cardiovascular adverse events.